| 14 September 2023 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Block Listing Interim Review
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: | Advanced Medical Solutions Group plc | |||
Name of scheme: | Block Scheme for: 1. Deferred Share Bonus Scheme 2. Company Share Option Plan 3. Unapproved Executive Share Option Scheme 4. Long Term Incentive Plan 5. Deferred Annual Bonus Scheme | |||
Period of return: | From: | 6 March 2023 | To: | 5 September 2023 |
Balance of unallotted securities under scheme(s) from previous return: | 1. 152,679 2. 182,253 3. 586,952 4. 274,107 5. 246,341 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. Nil 2. Nil 3. Nil 4. Nil 5. Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 1. 85,483 2. 40,710 3. 40,766 4. 47,585 5. Nil
| |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1. 67,196 2. 141,543 3. 546,186 4. 226,522 5. 246,341 | |||
Number and class of securities originally listed and the date of admission: | 4,476,264 ordinary shares of 5p each on 6 September 2018
| |||
Name of contact: | Eddie Johnson |
Telephone number of contact: | 01606 545506 |
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations | |
|
|
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Matthew Neal / Lucy Featherstone |
|
| |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Gary Clarence / David Anderson | |
| |
HSBC Bank plc (Broker) | Tel: +44 (0) 20 7991 8888 |
Sam McLennan / Joe Weaving / Stephanie Cornish | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.